These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 20827162)

  • 41. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy.
    Piconi S; Trabattoni D; Gori A; Parisotto S; Magni C; Meraviglia P; Bandera A; Capetti A; Rizzardini G; Clerici M
    AIDS; 2010 Aug; 24(13):1991-2000. PubMed ID: 20651586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.
    Buzón MJ; Massanella M; Llibre JM; Esteve A; Dahl V; Puertas MC; Gatell JM; Domingo P; Paredes R; Sharkey M; Palmer S; Stevenson M; Clotet B; Blanco J; Martinez-Picado J
    Nat Med; 2010 Apr; 16(4):460-5. PubMed ID: 20228817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination antiretroviral therapy with raltegravir leads to rapid immunologic reconstitution in treatment-naive patients with chronic HIV infection.
    Pallikkuth S; Fischl MA; Pahwa S
    J Infect Dis; 2013 Nov; 208(10):1613-23. PubMed ID: 23922374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
    Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
    Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a Phase II study.
    Gatell JM; Katlama C; Grinsztejn B; Eron JJ; Lazzarin A; Vittecoq D; Gonzalez CJ; Danovich RM; Wan H; Zhao J; Meibohm AR; Strohmaier KM; Harvey CM; Isaacs RD; Nguyen BY;
    J Acquir Immune Defic Syndr; 2010 Apr; 53(4):456-63. PubMed ID: 20306554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized controlled trial assessing the effects of raltegravir intensification on endothelial function in treated HIV infection.
    Hatano H; Scherzer R; Wu Y; Harvill K; Maka K; Hoh R; Sinclair E; Palmer S; Martin JN; Busch MP; Deeks SG; Hsue PY
    J Acquir Immune Defic Syndr; 2012 Nov; 61(3):317-25. PubMed ID: 22918156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery.
    Cillo AR; Hilldorfer BB; Lalama CM; McKinnon JE; Coombs RW; Tenorio AR; Fox L; Gandhi RT; Ribaudo H; Currier JS; Gulick RM; Wilkin TJ; Mellors JW
    AIDS; 2015 Oct; 29(16):2121-9. PubMed ID: 26544577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.
    Eron JJ; Cooper DA; Steigbigel RT; Clotet B; Gatell JM; Kumar PN; Rockstroh JK; Schechter M; Markowitz M; Yeni P; Loutfy MR; Lazzarin A; Lennox JL; Strohmaier KM; Wan H; Barnard RJ; Nguyen BY; Teppler H;
    Lancet Infect Dis; 2013 Jul; 13(7):587-96. PubMed ID: 23664333
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.
    Hunt PW; Shulman NS; Hayes TL; Dahl V; Somsouk M; Funderburg NT; McLaughlin B; Landay AL; Adeyemi O; Gilman LE; Clagett B; Rodriguez B; Martin JN; Schacker TW; Shacklett BL; Palmer S; Lederman MM; Deeks SG
    Blood; 2013 Jun; 121(23):4635-46. PubMed ID: 23589670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses.
    Lennox JL; Dejesus E; Berger DS; Lazzarin A; Pollard RB; Ramalho Madruga JV; Zhao J; Wan H; Gilbert CL; Teppler H; Rodgers AJ; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Sklar P;
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):39-48. PubMed ID: 20404738
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decreased PD-1 Expression on CD8 Lymphocyte Subsets and Increase in CD8 Tscm Cells in Children with HIV Receiving Raltegravir.
    Tuluc F; Spitsin S; Tustin NB; Murray JB; Tustin R; Schankel LA; Wiznia A; Nachman S; Douglas SD
    AIDS Res Hum Retroviruses; 2017 Feb; 33(2):133-142. PubMed ID: 27615375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Similar efficacy of raltegravir when used with or without a protease inhibitor in treatment-experienced patients.
    Skiest DJ; Cohen C; Mounzer K; Haigney Z; Barker D; Gottlieb M; Bellman PC; Dejesus E; Khanlou H; Ruane PJ; Hsiao CB; Abriola K; Rashbaum B; Bellos N; Ward D; Colson A; Santiago F; Habel A; Garb J
    HIV Clin Trials; 2011; 12(3):131-40. PubMed ID: 21684853
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials.
    Gutiérrez C; Hernández-Novoa B; Vallejo A; Serrano-Villar S; Abad-Fernández M; Madrid N; Díaz L; Moreno A; Dronda F; Zamora J; Muñoz-Fernández MA; Moreno S
    AIDS; 2013 Aug; 27(13):2081-8. PubMed ID: 24384589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).
    Gotuzzo E; Markowitz M; Ratanasuwan W; Smith G; Prada G; Morales-Ramirez JO; Strohmaier KM; Lu C; Bhanja S; Nguyen BY; Teppler H;
    J Acquir Immune Defic Syndr; 2012 Sep; 61(1):73-7. PubMed ID: 22743596
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment intensification followed by interleukin-7 reactivates HIV without reducing total HIV DNA: a randomized trial.
    Katlama C; Lambert-Niclot S; Assoumou L; Papagno L; Lecardonnel F; Zoorob R; Tambussi G; Clotet B; Youle M; Achenbach CJ; Murphy RL; Calvez V; Costagliola D; Autran B;
    AIDS; 2016 Jan; 30(2):221-30. PubMed ID: 26684819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunological benefits of antiretroviral therapy in very early stages of asymptomatic chronic HIV-1 infection.
    Plana M; García F; Gallart T; Tortajada C; Soriano A; Palou E; Maleno MJ; Barceló JJ; Vidal C; Cruceta A; Miró JM; Gatell JM
    AIDS; 2000 Sep; 14(13):1921-33. PubMed ID: 10997396
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model.
    Shytaj IL; Norelli S; Chirullo B; Della Corte A; Collins M; Yalley-Ogunro J; Greenhouse J; Iraci N; Acosta EP; Barreca ML; Lewis MG; Savarino A
    PLoS Pathog; 2012; 8(6):e1002774. PubMed ID: 22737073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.
    Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J
    Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
    Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
    Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection.
    Kaufmann GR; Zaunders JJ; Cunningham P; Kelleher AD; Grey P; Smith D; Carr A; Cooper DA
    AIDS; 2000 Dec; 14(17):2643-51. PubMed ID: 11125882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.